Ott G et al. |
Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59. |
1995 |
Vaccine |
pmid:8578842
|
Barnett SW et al. |
Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit. |
1997 |
Vaccine |
pmid:9234536
|
Hilgers LA et al. |
A novel non-mineral oil-based adjuvant. I. Efficacy of a synthetic sulfolipopolysaccharide in a squalane-in-water emulsion in laboratory animals. |
1994 |
Vaccine |
pmid:8085385
|
Hilgers LA et al. |
A novel non-mineral oil-based adjuvant. II. Efficacy of a synthetic sulfolipopolysaccharide in a squalane-in-water emulsion in pigs. |
1994 |
Vaccine |
pmid:8085386
|
Byars NE et al. |
Vaccinating guinea pigs with recombinant glycoprotein D of herpes simplex virus in an efficacious adjuvant formulation elicits protection against vaginal infection. |
1994 |
Vaccine |
pmid:8165851
|
Heineman TC et al. |
A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant. |
1999 |
Vaccine |
pmid:10438046
|
De Donato S et al. |
Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. |
1999 |
Vaccine |
pmid:10462245
|
Minutello M et al. |
Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. |
1999 |
Vaccine |
pmid:9987141
|
Iorio AM et al. |
Antibody responses and HIV-1 viral load in HIV-1-seropositive subjects immunised with either the MF59-adjuvanted influenza vaccine or a conventional non-adjuvanted subunit vaccine during highly active antiretroviral therapy. |
2003 |
Vaccine |
pmid:12922092
|
O'Hagan DT et al. |
Microparticles in MF59, a potent adjuvant combination for a recombinant protein vaccine against HIV-1. |
2000 |
Vaccine |
pmid:10699327
|
Black S et al. |
Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis. |
2010 |
Vaccine |
pmid:20813217
|
Madhun AS et al. |
An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers. |
2010 |
Vaccine |
pmid:21034828
|
Meier S et al. |
Antibody responses to natural influenza A/H1N1/09 disease or following immunization with adjuvanted vaccines, in immunocompetent and immunocompromised children. |
2011 |
Vaccine |
pmid:21419775
|
Parretta E et al. |
Italian post-marketing surveillance for adverse event reports after MF59-adjuvanted H1N1v vaccination. |
2011 |
Vaccine |
pmid:21406267
|
Garcia-Sicilia J et al. |
Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents. |
2011 |
Vaccine |
pmid:21504774
|
Decaro N et al. |
Immunogenicity and protective efficacy in dogs of an MF59â„¢-adjuvanted vaccine against recombinant canine/porcine coronavirus. |
2011 |
Vaccine |
pmid:21272607
|
Calabro S et al. |
Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. |
2011 |
Vaccine |
pmid:21215831
|
Javelle E et al. |
Delayed focal lipoatrophy after AS03-adjuvanted influenza A (H1N1) 2009 vaccine. |
2011 |
Vaccine |
pmid:21172376
|
Esposito S et al. |
Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents. |
2011 |
Vaccine |
pmid:21199699
|
Pellegrini M et al. |
MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database. |
2009 |
Vaccine |
pmid:19751689
|
Forrest HL et al. |
Single- and multiple-clade influenza A H5N1 vaccines induce cross protection in ferrets. |
2009 |
Vaccine |
pmid:19406182
|
Vesikari T et al. |
MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination. |
2009 |
Vaccine |
pmid:19840662
|
Ansaldi F et al. |
Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates. |
2010 |
Vaccine |
pmid:20433807
|
Tsai T et al. |
Exposure to MF59-adjuvanted influenza vaccines during pregnancy--a retrospective analysis. |
2010 |
Vaccine |
pmid:19969117
|
Pietrella D et al. |
A beta-glucan-conjugate vaccine and anti-beta-glucan antibodies are effective against murine vaginal candidiasis as assessed by a novel in vivo imaging technique. |
2010 |
Vaccine |
pmid:20038431
|
Camilloni B et al. |
An influenza B outbreak during the 2007/2008 winter among appropriately immunized elderly people living in a nursing home. |
2010 |
Vaccine |
pmid:20846530
|
Fabbiani M et al. |
Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients. |
2011 |
Vaccine |
pmid:21349364
|
Della Cioppa G et al. |
Trivalent and quadrivalent MF59(®)-adjuvanted influenza vaccine in young children: a dose- and schedule-finding study. |
2011 |
Vaccine |
pmid:21906647
|
Fox CB et al. |
Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions. |
2011 |
Vaccine |
pmid:21906648
|
Radosević K et al. |
Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants. |
2008 |
Vaccine |
pmid:18514980
|
Brito LA et al. |
An alternative renewable source of squalene for use in emulsion adjuvants. |
2011 |
Vaccine |
pmid:21723355
|
Puig-Barberà J et al. |
Effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly. |
2007 |
Vaccine |
pmid:17889411
|
de Bruijn I et al. |
Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly. |
2007 |
Vaccine |
pmid:18063446
|
Wack A et al. |
Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. |
2008 |
Vaccine |
pmid:18162266
|
Singh M et al. |
A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens. |
2006 |
Vaccine |
pmid:16300864
|
Puig-Barberà J et al. |
Effectiveness of the MF59-adjuvanted influenza vaccine in preventing emergency admissions for pneumonia in the elderly over 64 years of age. |
2004 |
Vaccine |
pmid:15530669
|
Del Giudice G et al. |
An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine. |
2006 |
Vaccine |
pmid:16464520
|
Schultze V et al. |
Safety of MF59 adjuvant. |
2008 |
Vaccine |
pmid:18462843
|
Pariani E et al. |
Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy. |
2011 |
Vaccine |
pmid:21974995
|
Andrews NJ et al. |
Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines. |
2011 |
Vaccine |
pmid:21875635
|
Iorio AM et al. |
Influenza viruses and cross-reactivity in healthy adults: humoral and cellular immunity induced by seasonal 2007/2008 influenza vaccination against vaccine antigens and 2009 A(H1N1) pandemic influenza virus. |
2012 |
Vaccine |
pmid:22245606
|
Fukase H et al. |
Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects. |
2012 |
Vaccine |
pmid:22472791
|
Hatz C et al. |
A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects. |
2012 |
Vaccine |
pmid:22446638
|
O'Hagan DT et al. |
The mechanism of action of MF59 - an innately attractive adjuvant formulation. |
2012 |
Vaccine |
pmid:22682289
|
Yu S et al. |
Novel Th1-biased adjuvant, SPO1, enhances mucosal and systemic immunogenicity of vaccines administered intranasally in mice. |
2012 |
Vaccine |
pmid:22709954
|
Tetsutani K and Ishii KJ |
Adjuvants in influenza vaccines. |
2012 |
Vaccine |
pmid:23084848
|
Nielsen AB et al. |
Immune response after one or two doses of pandemic influenza A (H1N1) monovalent, AS03-adjuvanted vaccine in HIV infected adults. |
2012 |
Vaccine |
pmid:23036498
|
Van Buynder PG et al. |
The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly. |
2013 |
Vaccine |
pmid:23933368
|
Vinay TN et al. |
Inactivated vaccine against viral hemorrhagic septicemia (VHS) emulsified with squalene and aluminum hydroxide adjuvant provides long term protection in olive flounder (Paralichthys olivaceus). |
2013 |
Vaccine |
pmid:23896420
|
Poder A et al. |
An observer-blind, randomized, multi-center trial assessing long-term safety and immunogenicity of AS03-adjuvanted or unadjuvanted H1N1/2009 influenza vaccines in children 10-17 years of age. |
2014 |
Vaccine |
pmid:24252703
|